All questionsSafety: Ibrance (palbociclib), all indications9 questions · 3 sourcesSafety managementWhich infection or low blood count symptoms should Ibrance patients report?“Advise patients to immediately report any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, weakness, or any increased tendency to bleed and/or to bruise [see Warnings and Precautions (5.1)].” (opens the source at this quote in a new tab)CopyFlagWarningsWhat are the warnings and precautions for Ibrance?“WARNINGS AND PRECAUTIONS • Neutropenia: Monitor complete blood count prior to start of IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated. (2.2, 5.1) • Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/pneumonitis have been reported. Monitor for pulmonary symptoms of ILD/pneumonitis. Interrupt IBRANCE immediately in patients with suspected ILD/pneumonitis. Permanently discontinue IBRANCE if severe ILD/pneumonitis occurs. (5.2) • Embryo-Fetal Toxicity: IBRANCE can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.3, 8.1, 8.3)” (opens the source at this quote in a new tab)CopyFlagDoes Ibrance have any contraindications?“4 CONTRAINDICATIONS None.” (opens the source at this quote in a new tab)CopyFlagSide effectsHave blood clots (venous thromboembolism) been reported with Ibrance?“The following adverse reaction has been reported following administration of IBRANCE: venous thromboembolism.” (opens the source at this quote in a new tab)CopyFlagWhat Ibrance side effects were reported after approval?“The following adverse reactions have been identified during post-approval use of IBRANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory Disorders: Interstitial lung disease (ILD)/non-infectious pneumonitis Skin and Subcutaneous Tissue Disorders: Palmar-plantar erythrodysesthesia syndrome (PPES)” (opens the source at this quote in a new tab)CopyFlagSafetyDoes Ibrance affect the QT interval?“The effect of palbociclib on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline and corresponding pharmacokinetic data in 77 patients with breast cancer. Palbociclib had no large effect on QTc (i.e., >20 ms) at 125 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.” (opens the source at this quote in a new tab)CopyFlag“In a QTc substudy of 77 patients from PALOMA-2, no large effect (>20 ms) on the QTc interval was observed in patients taking IBRANCE1-3” (opens the source at this quote in a new tab)CopyFlag“In this substudy, the mean change from baseline for QTc was <8 ms with IBRANCE at all postbaseline time points in the QTc assessment period vs <7 ms in the control arm3” (opens the source at this quote in a new tab)CopyFlagDo Ibrance tablets and capsules differ in side effects?“The efficacy and safety data in the tablet label are based on the clinical trials conducted with the capsule formulation. The benefit and risk profile of IBRANCE tablets is expected to be similar to that of the capsules.1,2” (opens the source at this quote in a new tab)CopyFlagMonitoringHow often are blood counts checked during Ibrance treatment?“Monitor CBCs prior to the start of IBRANCE therapy, on Days 1 and 15 of the first 2 cycles, on Day 1 of subsequent cycles, and as clinically indicated1,2” (opens the source at this quote in a new tab)CopyFlag“The frequency of CBC monitoring can decrease over time1,2” (opens the source at this quote in a new tab)CopyFlag“For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, monitor CBCs for subsequent cycles every 3 months, prior to the beginning of a cycle, and as clinically indicated.” (opens the source at this quote in a new tab)CopyFlag“When scheduling Day 15 monitoring and subsequent follow-up visits, remember to consider when the patient actually receives their medication and initiates each cycle.” (opens the source at this quote in a new tab)CopyFlagDoes Ibrance require ECG or liver enzyme monitoring?“ECG, serum electrolyte, or liver enzyme tests are not required in the current IBRANCE Prescribing Information1,2” (opens the source at this quote in a new tab)CopyFlag“Additional monitoring may be necessary based on the individual patient1,2” (opens the source at this quote in a new tab)CopyFlag